Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
$7.87
+0.1%
$9.73
$5.01
$12.75
$487.47M2.48687,828 shs183,171 shs
Heska Co. stock logo
HSKA
Heska
$119.99
$119.09
$57.83
$120.03
$1.31B1.58241,932 shsN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$57.92
+6.9%
$63.61
$27.02
$73.00
$2.09B1.26411,766 shs144,273 shs
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
$24.65
-0.8%
$28.68
$22.05
$45.79
$3.12B2.71895,329 shs422,137 shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
-2.96%-6.65%-15.57%-26.47%-3.79%
Heska Co. stock logo
HSKA
Heska
0.00%0.00%0.00%0.00%+2.59%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-3.65%-8.07%-18.03%-5.36%+24.60%
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
-2.59%+6.06%-14.90%-21.57%-37.16%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
1.2536 of 5 stars
3.51.00.00.02.31.70.0
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/AN/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
2.0697 of 5 stars
4.51.00.00.00.03.30.0
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
2.0945 of 5 stars
3.41.00.00.02.00.81.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
3.00
Buy$47.40502.29% Upside
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
3.00
Buy$86.0048.48% Upside
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
2.88
Moderate Buy$43.6376.98% Upside

Current Analyst Ratings

Latest CMPS, HSKA, KROS, SGRY, and RHK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
4/10/2024
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$43.00
4/1/2024
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$30.00
3/27/2024
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00
3/13/2024
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00
3/6/2024
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$35.00
3/5/2024
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$43.00
3/1/2024
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00
3/1/2024
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00
2/29/2024
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$86.00
2/29/2024
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$49.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/A$3.65 per shareN/A
Heska Co. stock logo
HSKA
Heska
$257.31M5.09$1.69 per share70.99$39.00 per share3.08
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$150K13,927.83N/AN/A$11.09 per share5.22
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
$2.74B1.14$1.74 per share14.20$23.99 per share1.03

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
-$118.46M-$2.39N/AN/AN/AN/A-58.72%-49.46%5/9/2024 (Estimated)
Heska Co. stock logo
HSKA
Heska
-$19.89M-$1.93N/A83.33N/A-7.86%0.94%0.67%N/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$152.99M-$5.20N/AN/AN/AN/A-46.74%-42.59%5/2/2024 (Estimated)
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
-$11.90M-$0.10N/A23.252.33-0.43%3.65%1.62%5/7/2024 (Confirmed)

Latest CMPS, HSKA, KROS, SGRY, and RHK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
$0.0720N/A-$0.0720N/AN/AN/A  
3/1/2024Q4 2023
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$1.37-$1.34+$0.03-$1.34N/A$0.14 million
2/29/2024Q4 2023
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
-$0.37-$0.53-$0.16-$0.53N/AN/A
2/26/202412/31/2023
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
$0.3730$0.44+$0.0670$0.81$741.93 million$735.40 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/AN/A
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/AN/AN/AN/AN/A
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
0.14
13.33
13.33
Heska Co. stock logo
HSKA
Heska
0.23
5.64
4.12
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/A
14.25
14.25
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
0.89
1.71
1.57

Ownership

Institutional Ownership

CompanyInstitutional Ownership
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
46.19%
Heska Co. stock logo
HSKA
Heska
99.01%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
71.56%
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
N/A

Insider Ownership

CompanyInsider Ownership
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
4.25%
Heska Co. stock logo
HSKA
Heska
12.30%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
28.00%
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
2.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
18661.94 million59.31 millionOptionable
Heska Co. stock logo
HSKA
Heska
80810.91 million9.57 millionNot Optionable
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
13636.07 million25.97 millionOptionable
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
13,500126.61 million123.32 millionOptionable

CMPS, HSKA, KROS, SGRY, and RHK Headlines

SourceHeadline
Should You Invest in Surgery Partners (SGRY)?Should You Invest in Surgery Partners (SGRY)?
finance.yahoo.com - April 24 at 8:18 AM
Surgery Partners (NASDAQ:SGRY) Stock Price Down 3.9%Surgery Partners (NASDAQ:SGRY) Stock Price Down 3.9%
marketbeat.com - April 18 at 2:47 PM
Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call DetailsSurgery Partners, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call Details
globenewswire.com - April 18 at 1:06 AM
Surgery Partners Enters Oversold Territory (SGRY)Surgery Partners Enters Oversold Territory (SGRY)
nasdaq.com - April 17 at 12:52 AM
WCM Investment Management LLC Has $16.27 Million Position in Surgery Partners, Inc. (NASDAQ:SGRY)WCM Investment Management LLC Has $16.27 Million Position in Surgery Partners, Inc. (NASDAQ:SGRY)
marketbeat.com - April 14 at 10:37 AM
Surgery Partners (NASDAQ:SGRY) Shares Up 2.6%Surgery Partners (NASDAQ:SGRY) Shares Up 2.6%
marketbeat.com - April 12 at 3:16 PM
SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?
zacks.com - April 11 at 12:41 PM
Surgery Partners (SGRY) Overweight Rating Reaffirmed at Cantor FitzgeraldSurgery Partners' (SGRY) Overweight Rating Reaffirmed at Cantor Fitzgerald
marketbeat.com - April 10 at 11:26 AM
Surgery Partners, Inc. (NASDAQ:SGRY) Given Consensus Rating of "Moderate Buy" by BrokeragesSurgery Partners, Inc. (NASDAQ:SGRY) Given Consensus Rating of "Moderate Buy" by Brokerages
marketbeat.com - April 8 at 2:32 AM
Redwood Investments LLC Trims Stake in Surgery Partners, Inc. (NASDAQ:SGRY)Redwood Investments LLC Trims Stake in Surgery Partners, Inc. (NASDAQ:SGRY)
marketbeat.com - April 1 at 6:48 AM
Vanguard Group Inc. Sells 59,376 Shares of Surgery Partners, Inc. (NASDAQ:SGRY)Vanguard Group Inc. Sells 59,376 Shares of Surgery Partners, Inc. (NASDAQ:SGRY)
marketbeat.com - March 31 at 4:08 AM
Surgery Partners, Inc. (NASDAQ:SGRY) to Post Q2 2024 Earnings of $0.11 Per Share, Leerink Partnrs ForecastsSurgery Partners, Inc. (NASDAQ:SGRY) to Post Q2 2024 Earnings of $0.11 Per Share, Leerink Partnrs Forecasts
marketbeat.com - March 29 at 8:36 AM
Surgery Partners: A Buy Rating Amidst Underperformance and Growth PotentialSurgery Partners: A Buy Rating Amidst Underperformance and Growth Potential
markets.businessinsider.com - March 29 at 7:22 AM
Surgery Partners to offer $600M senior unsecured notesSurgery Partners to offer $600M senior unsecured notes
seekingalpha.com - March 26 at 11:06 PM
Surgery Partners, Inc. Announces Pricing of New Senior Notes OfferingSurgery Partners, Inc. Announces Pricing of New Senior Notes Offering
globenewswire.com - March 26 at 3:51 PM
Surgery Partners, Inc. Announces New Senior Notes OfferingSurgery Partners, Inc. Announces New Senior Notes Offering
globenewswire.com - March 26 at 8:21 AM
Investors Met With Slowing Returns on Capital At Surgery Partners (NASDAQ:SGRY)Investors Met With Slowing Returns on Capital At Surgery Partners (NASDAQ:SGRY)
finance.yahoo.com - March 25 at 4:22 PM
Surgery Partners (SGRY) Upgraded to Buy: What Does It Mean for the Stock?Surgery Partners (SGRY) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com - March 20 at 1:01 PM
Insider Selling: Surgery Partners, Inc. (NASDAQ:SGRY) CEO Sells 1,984 Shares of StockInsider Selling: Surgery Partners, Inc. (NASDAQ:SGRY) CEO Sells 1,984 Shares of Stock
insidertrades.com - March 14 at 9:52 AM
Remission Medical partners with OrthoVirginiaRemission Medical partners with OrthoVirginia
beckersspine.com - March 14 at 2:23 AM
New Surgery Center Wraps in Silicon ValleyNew Surgery Center Wraps in Silicon Valley
hconews.com - March 11 at 3:05 PM
Insider Sell: CFO David Doherty Sells 3,426 Shares of Surgery Partners Inc (SGRY)Insider Sell: CFO David Doherty Sells 3,426 Shares of Surgery Partners Inc (SGRY)
finance.yahoo.com - March 7 at 10:26 AM
Surgery Partners initiated with neutral view at BarclaysSurgery Partners initiated with neutral view at Barclays
realmoney.thestreet.com - March 6 at 6:41 PM
Surgery Partners, Inc. (NASDAQ:SGRY) Q4 2023 Earnings Call TranscriptSurgery Partners, Inc. (NASDAQ:SGRY) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 1 at 12:04 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

COMPASS Pathways logo

COMPASS Pathways

NASDAQ:CMPS
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Heska logo

Heska

NASDAQ:HSKA
Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.
Keros Therapeutics logo

Keros Therapeutics

NASDAQ:KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Surgery Partners logo

Surgery Partners

NASDAQ:SGRY
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.